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Abstract
Background: Proadrenomedullin (ProADM) confers additional prognostic information to established clinical risk
scores in lower respiratory tract infections (LRTI). We aimed to derive a practical algorithm combining the CURB65
score with ProADM-levels in patients with community-acquired pneumonia (CAP) and non-CAP-LRTI.
Methods: We used data of 1359 patients with LRTI enrolled in a multicenter study. We chose two ProADM cut-off
values by assessing the association between ProADM levels and the risk of adverse events and mortality. A
composite score (CURB65-A) was created combining CURB65 classes with ProADM cut-offs to further risk-stratify
patients.
Results: CURB65 and ProADM predicted both adverse events and mortality similarly well in CAP and non-CAP-LRTI.
The combined CURB65-A risk score provided better prediction of death and adverse events than the CURB65 score
in the entire cohort and in CAP and non-CAP-LRTI patients. Within each CURB65 class, higher ProADM-levels were
associated with an increased risk of adverse events and mortality. Overall, risk of adverse events (3.9%) and
mortality (0.65%) was low for patients with CURB65 score 0-1 and ProADM ≤0.75 nmol/l (CURB65-A risk class I);
intermediate (8.6% and 2.6%, respectively) for patients with CURB65 score of 2 and ProADM ≤1.5 nmol/l or CURB
classes 0-1 and ProADM levels between 0.75-1.5 nmol/L (CURB65-A risk class II), and high (21.6% and 9.8%,
respectively) for all other patients (CURB65-A risk class III). If outpatient treatment was recommended for CURB65-A
risk class I and short hospitalization for CURB65-A risk class II, 17.9% and 40.8% of 1217 hospitalized patients could
have received ambulatory treatment or a short hospitalization, respectively.
Conclusions: The new CURB65-A risk score combining CURB65 risk classes with ProADM cut-off values accurately
predicts adverse events and mortality in patients with CAP and non-CAP-LRTI. Additional prospective cohort or
intervention studies need to validate this score and demonstrate its safety and efficacy for the management of
patients with LRTI.
Trial Registration: Procalcitonin-guided antibiotic therapy and hospitalisation in patients with lower respiratory
tract infections: the prohosp study; isrctn.org Identifier: ISRCTN: ISRCTN95122877
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Lower respiratory tract infections (LRTIs) comprising
community-acquired pneumonia (CAP), exacerbation of
chronic obstructive pulmonary disease (COPD) and
acute bronchitis, are the most important infectious
causes of death in industrialized countries [1]. In the
management of CAP, assessment of disease severity and
prediction of outcome is essential for a rational alloca-
tion of health care resources and for guiding therapeutic
options. For this purpose, different risk assessment tools
have been developed. The CURB65 is a widely used risk
assessment tool [2,3]. It relies on only five predictors, is
relatively easy to memorize and calculate, and demon-
strates better practicability than other scores [4,5]. How-
ever, it conceptually is a static score and lacks
i n f o r m a t i o no nt h eh o s t ’s inflammatory response. The
score was validated to predict mortality only and has
not been proven to predict other CAP-associated
adverse outcomes. CURB65 has been validated in many
studies for CAP patients, and to a lesser extent in other
non-CAP-LRTI patients [6,7]. It provides only limited
discriminatory power with moderate sensitivity and spe-
cificity. This potentially leads to hospitalization of low-
risk patients where outpatie n tt r e a t m e n tw o u l db ep r e -
ferable, and conversely, to outpatient treatment of high-
risk patients [4]. Thus, there is increasing interest in
new risk factors and biomarkers that confer additional
prognostic information [8,9].
Several candidate hormones have been proposed,
among which proadrenomedullin (ProADM) proved to
be the most promising in patients with sepsis [10-12],
CAP [13-15] and other LRTIs [13,16]. ProADM belongs
to the calcitonin peptide superfamily and emerges from
the CALC V gene with distinct molecular regulation
and various effects, including potent vasodilatation,
immune modulation and bactericidal activity [16,17].
ProADM is a “hormokine”, characterized by a hormone-
like behavior in non-inflammatory conditions when it is
produced only by endocrine cells; and a cytokine-like
behavior in septic conditions when it is ubiquitously
hyper-expressed [18,19]. We recently validated the prog-
nostic performance of ProADM in a large cohort of
LRTI patients from a multicenter study [13]. A precise
clinical algorithm for future routine use, however,
remains to be established. The aim of this analysis was,
therefore, to derive a risk score based on CURB65
classes enhanced by ProADM cut-off ranges for
improved prognostic assessment in CAP and non-CAP-
LRTIs as a basis for future intervention studies.
Methods
Study Design and Setting
From October 2006 to March 2008, 1359 consecutive
patients with presumed LRTI from six Swiss hospitals
were included in the randomized controlled ProHOSP
study to determine the safety of procalcitonin-guided
antimicrobial therapy [20,21]. As a predefined secondary
endpoint, we investigated the prognostic potential of
ProADM and other biomarkers.
Selection of participants
Adult patients (>18 years) with LRTI as principal diag-
nosis on admission were eligible as previously described
[20]. CAP was defined as a new infiltrate on chest radio-
graph; COPD by spirometric criteria, according to the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines; acute bronchitis by LRTI in the
absence of an underlying lung disease or focal clinical
and radiological findings [22-25]. For all patients, the
CURB65 was calculated on admission [3]. The study
protocol was approved by all local ethical committees,
and written informed consent was obtained from all
participants.
Methods of ProADM measurement
ProADM was collected on admission (day 0) and on
days 3, 5 and 7 and batch-measured in a blinded fashion
with a sandwich immunoassay with an analytical detec-
tion limits of 0.08 nmol/L as described elsewhere [26].
Study endpoints
The primary endpoint for this analysis was a composite
of adverse events defined as death of any cause, inten-
sive care unit (ICU) admission, or any disease specific
complications (i.e, persistence or development of pneu-
monia, lung abscess, empyema, and acute respiratory
distress syndrome) within 30 days after enrollment. The
secondary endpoint was all-cause 30-day mortality. We
displayed internationally-accepted severity criteria
according to the 2001 American Thoracic Society
recommendations on a study web-site [24]. In brief, we
recommended that patients should be assessed for need
of transfer to the ICU if they had severe CAP [27],
defined as the presence of either one of two major cri-
teria (need for mechanical ventilation, septic shock), the
presence of two of three minor criteria (systolic blood
pressure <90 mmHg, multilobar disease, PaO2/FIO2
ratio <250), or more than 2 CURB65 points [3]. For
COPD patients, severity was defined based on modified
ERS guidelines [28], including severe acidosis or respira-
tory failure (pH<7.3, pO2<6.7 kPa, pCO2>9.3 kPa), no
response to initial treatment in the emergency depart-
ment or worsening mental status (confusion, coma)
despite adequate therapy. Yet, these recommendations
were not mandatory and the final decision for ICU
transfer was a clinical decision made by the attending
physician in charge who also incorporated the social
situation, patient’s requests and the hospital capacity
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treatment within the ProHOSP study, which was defined
as discharge from the hospital or emergency department
after 1 day or less.
Standardized outcome assessment was performed dur-
ing hospital stay and by structured phone interviews on
day 30 by trained medical students. It was monitored by
an independent Data Safety and Monitoring Board con-
sisting of 3 specialists in pulmonary medicine, infectious
diseases and intensive care medicine as part of the study
protocol [21]. If the patient indicated any complication
during or following hospital discharge, or was unable to
give adequate information, respectively, the interviewer
contacted the treating physician or the hospital to
obtain further information or the discharge letter.
Statistical Analysis
The primary analysis population contained all 1359
patients with presumed LRTI from the ProHOSP study.
We also calculated results for CAP and non-CAP-LRTI
patients separately. As described previously [13], we
used imputations to deal with missing CURB65 covari-
ates and ProADM values. The imputation dataset con-
sisted of all 1359 ProHOSP patients and the following
variables: all covariates included in the derivation of the
pneumonia severity index (PSI) or CURB65 scores, bio-
marker values on day 0, 3, 5, and 7, randomization arm,
final diagnosis, total antibiotic exposure, length of hospi-
tal stay as well as death, ICU admission, complication,
or disease recurrence within 30 days of randomization.
Outcomes were also included in the imputation to avoid
bias. We then used average values over five imputed
datasets for the final analysis.
First, we visualized the (smoothed) association
between ProADM levels on admission and the risk of
serious complications or mortality, respectively, based
on a generalized additive model for each CURB65 risk
category (CURB65 0-1; 2; 3-5). We tested whether
ProADM improves the performance of the CURB65
s c o r eb yc o m p a r i n gR O Cc u r v e so ft h ej o i n tl o g i s t i c
regression of ProADM and the CURB65 to ROC curves
limited to the CURB65 only. We then calculated sepa-
rate logistic regression models for serious complications
and death with log-transformed ProADM-levels as the
sole covariate within CURB65 risk categories. Predicted
and observed probabilities for both endpoints were dis-
played within deciles of ProADM and goodness-of-fit
assessed with the Hosmer-Lemeshow test. Based on
these analyses, we chose two ProADM cut-off values
which meaningfully separated patients as low or high
risk. A composite score (CURB65-A) was created com-
bining CURB65 class with ProADM cut-offs to further
stratify patients in low (CURB65-A risk class I), inter-
mediate (CURB65-A risk class II) and high risk
(CURB65-A risk class III). We then investigated the
clinical usefulness of these cut-off values and risk classes
by calculating observed risks based on the ProHOSP
study sample.
Finally, we investigated the potential utility of the
CURB65-A score for triage decisions.
A l lt e s t i n gw a st w o - t a i l e da n dpv a l u e sl e s st h a n0 . 0 5
were considered to indicate statistical significance. All
calculations were performed using STATA 9.2 (Stata
Corp, College Station, Texas).
Results
Patient population
A total of 1359 patients (58% males, median age 73
years) with initial suspicion of LRTI were included
(Table 1). Of these, 1304 had a definite diagnosis of
LRTI including 925 patients with CAP, 228 patients
with exacerbation of COPD, and 151 patients with acute
bronchitis. At least one comorbidity was observed in
>70% of patients.
Performance of CURB65 and ProADM overall and in CAP
and non-CAP-LRTI
Overall, 12.2% of patients experienced an adverse event
within 30 days of enrollment, including death (4.9%)
and ICU admission (7.6%). Disease-specific complica-
tions - all of them empyema - occurred in 2.4% and
only in CAP patients. CURB65 and initial ProADM
showed a similar performance in the overall cohort, and
in patients with CAP and non-CAP-LRTI (Table 2).
Addition of ProADM to CURB65 score for mortality and
adverse event prediction
When adding ProADM to the CURB65 score in a joint
logistic regression model, the combined model showed a
significant improvement of the CURB65 score alone for
mortality prediction and adverse event prediction in
ROC statistics. The AUC of the combined model in the
overall cohort was 0.81 (95%CI: 0.77-0.86) for mortality
prediction and 0.74 (95%CI: 0.70-0.79) for adverse event
prediction (p < 0.0001 compared to CURB65 score for
both comparisons). For CAP patients, the respective
AUCs were 0.80 (0.73-0.86; p < 0.00001) and 0.73 (0.68-
0.78; p < 0.00001); for non-CAP-LRTI patients the
AUCs were 0.88 (0.81-0.95; p < 0.05) and 0.76 (0.67-
0.85; p < 0.01).
Predicted risks of ProADM and optimal cut-off values
In Figure 1, the estimated smoothed associations
between admission ProADM levels and predicted
adverse events risks (black line) and predicted mortality
risk (blue line) are displayed. Hosmer-Lemeshow good-
ness of fit test showed no evidence for miscalibration
(p > 0.05 for all calculations) in the plots based on a
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mortality for ProADM within CURB65 groups. Within
low risk CURB65 classes 0 and 1, patients in the lowest
three ProADM deciles (approximately corresponding to
a ProADM level of <0.75 nmol/L), the probability for
adverse events was <5% and the probability for mortality
was <0.5%, but increased to >20% and >3% in the high-
est decile (Figure 2). Within a priori high-risk CURB65
classes 3-5, the risk for adverse events and mortality
increased to >20% and >9% in the highest three deciles
of ProADM levels (approximately corresponding to a
ProADM level of >1.5 nmol/L) (Figure 3).
ProADM enhanced CURB65 risk score - CURB65-A
We assessed observed risks for adverse outcome and
mortality within all patients and within CAP patients
only based on the two ProADM cut offs and the three
ap r i o r iC U R B 6 5r i s kg r o u p s( T a b l e3F i g u r e s4&5 ) .
Thereby, patients in lowest CURB65 groups and with
ProADM levels of <0.75 nmol/L had very low risks for
both adverse events and mortality (CURB65-A risk class
I). Conversely, patients in the highest CURB65 group
and in the highest ProADM groups (CURB65-A risk
class III) had high risk for adverse events and for
mortality. Only 11 patients had ProADM levels of
<0.75 nmol/L but were in the highest CURB65 classes
3-5 and none of them had an adverse outcome. Finally,
patients within CURB65 class 2 but with ProADM levels
of <1.5 nmol/L or CURB classes 0-1 and ProADM levels
between 0.75-1.5 nmol/L had intermediate risks
(CURB65-A risk class II). In patients with high CURB65
classes, increasing ProADM levels indicated increasing
risk of adverse events and of mortality (p for trend 0.03
and p = 0.09, respectively, in CURB65 class 2; and p for
trend <0.001 and p = 0.02, respectively, in CURB65
classes 3-5). In low-risk patients (CURB65 classes 0-1)
increasing ProADM levels provided no additional infor-
mation on mortality risk (p for trend: 0.98), but indi-
cated significantly increased risk of adverse events (p for
trend: 0.008).
Potential effects on triage decisions
We further assessed potential impact of this new risk
score on in- and outpatient treatment. Of 142 patients
who were treated as outpatients, ambulatory treatment
would indeed be recommended for 88 (62.0%; risk class
I), whereas in 38 (26.8%) short hospitalization (risk class
II) and in 16 (11.3%) hospitalization (risk class III)
would be recommended based on CURB65-A (Figure 6).
Conversely, in 218 (17.8%) and 496 (40.8%) of the 1217
hospitalized patients, outpatient treatment or a short
hospitalization would be recommended according to
CURB65-A risk.
Discussion
Combining CURB65 classes with the prognostic infor-
mation of ProADM in a new risk classification
(CURB65-A score) offers improved risk prediction with
regard to both adverse events and mortality in CAP and
non-CAP-LRTI patients. This could lead to reclassifica-
tion of alleged low-risk patients based on the CURB65
classification into higher risk classes and consecutive
inpatient treatment; at the same time, almost 20% of
patients who were treated as inpatients would be con-
sidered low risk based on CURB65-A and outpatient
treatment would be strongly recommended. Thus, the
results of his study suggest that the CURB65-A score
can efficiently and safely increase the proportion of out-
patient treatment in all LRTI patients, CAP and non-
CAP.
Both PSI and CURB65 are recommended by guide-
lines for site of care decision in patients with CAP [29].
Table 1 Baseline characteristics
Characteristics All patients (n = 1359)
Demographic characteristics
Age (years)* 73 (59-82)
Sex (male) - no. (%) 782 (57.5)
Coexisting illnesses - no. (%)
Coronary heart disease 282 (20.8)
Cerebrovascular disease 110 (8.1)
Renal dysfunction 302 (22.2)
COPD 533 (39.2)
Neoplastic disease 167 (12.3)
Diabetes 231 (17.0)
Any coexisting illness 963 (70.9)
Clinical history - no. (%)
Cough 1164 (88.7)
Expectorations 678 (50.9)
Dyspnea 1009 (77.0)
Fever 782 (57.9)
Chills 362 (32.0)
Clinical findings
Confusion - no. (%) 84 (6.8)
Respiratory rate (breaths/min)* 20 (16-25)
Systolic blood pressure (mmHg)* 134 (120-150)
Heart rate (beats/minute)* 93 (80-106)
Body temperature (C°)* 37.8 (37.0-38.6)
Rales - no. (%) 832 (64.1)
Final diagnosis - no. (%)
Community-acquired pneumonia (CAP) 925 (68.1)
Exacerbation of COPD 228 (16.8)
Bronchitis 151 (11.1)
Other final diagnosis 55 (4.0)
COPD, chronic obstructive pulmonary disease; CAP, community-acquired
pneumonia; PSI, pneumonia severity index; higher PSI class refers to higher
risk for mortality; *expressed as median (Interquartile range, IQR);
Note: there was no statistical difference in baseline characteristic between
both groups.
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mortality [3,5,30], while daily decisions have to take into
account other adverse outcomes, in addition to comor-
bidities and non-medical factors. In the ProHOSP study,
fear of adverse medical outcome was one of the most
important perceived reasons by healthcare providers
leading to hospital admission. This was true indepen-
dent of medical risks as assessed with clinical risk scores
[31]. In the ProHOSP study, 8.7% patients with CURB65
score 0-1 had an adverse event and 0.9% died, which
may be considered unacceptably high by many physi-
cians and patients to recommend or accept outpatient
treatment. Therefore, in reality, triage decisions in CAP
patients are not always based on these clinical risk
scores [32] and are not even evidence- or guideline-
based for non-CAP-LRTI. Obvious advantages of outpa-
tient treatment include a reduced risk of health-care
associated infections [33] and other nosocomial compli-
cations such as falls or delirium of elderly patients [34].
Outpatient treatment is preferred by most patients [35],
improves patient and relatives’ satisfaction [36], and
would importantly free scarce resources in many
healthcare settings, which face considerable bed
shortages during the respiratory season [37]. In addition,
inpatient treatment for LRTI is 8-20 times more expen-
sive than outpatient treatment [24,36,38]. Marrie et al.
[39] demonstrated that 13.5% of CAP patients with high
risk based on a PSI level of IV or V, could be safely
treated as outpatients with only 0.6% of those requiring
ultimate hospital admission and a 0.6% mortality.
Thus, modified and improved triage algorithms are
necessary [40], and new clinical pathways have been
proposed [41,42]. Both of these studies were performed
in Canada and little data is available on the generaliz-
ability and routine applicability of these complex path-
ways. Yealy et al. [43] used graded-intensity level
measures to improve guideline utilization in a trial-set-
ting in US emergency departments. However, the neces-
sary efforts raise doubt about the feasibility in daily
routine.
In contrast, readily available biomarkers which are
easy to measure and quantify, might provide objective
and dynamic measurements supporting clinical judg-
ment. In addition, such biomarkers may provide an
Table 2 Outcomes and performance of risk scores and ProADM overall and in CAP and non-CAP-LRTI
Parameters All patients (n = 1359) CAP
(n = 925)
Non-CAP
(n = 379)
P*
30 days outcomes
Outpatient treatment, no (%) 142 (10%) 81 (9%) 61 (16%) <0.001
Length of hospital stay, median (IQR) 8 (4-12) 8 (5-12) 7 (3-11) <0.001
All cause mortality, no (%) 67 (4.9%) 50 (5.4%) 10 (2.6%) 0.03
ICU admission, no (%) 103 (7.6%) 83 (9.0%) 15 (4.0%) 0.002
Empyema, no (%) 31 (2.4%) 31 (3.3%) 0 <0.001
Any adverse events, no (%) 170 (12.2%) 134 (14.5%) 24 (6.3%) <0.001
CURB65 score
CURB65 points, median (IQR) 2 (1-2) 2 (1-2) 1 (1-2) 0.002
CURB65 risk classes 0.001
CURB65 0-1, no (%) 659 (48.5%) 427 (46.2%) 211 (55.7%)
CURB65 2, no (%) 434 (31.9%) 296 (32.0%) 114 (30.1%)
CURB65 3-5, no (%) 266 (19.6%) 202 (21.8%) 54 (14.2%)
AUC of CURB65 risk classes for adverse events (95%CI) 0.65 (0.61-0.69) 0.64 (0.59-0.65) 0.68 (0.57-0.78)
AUC of CURB65 risk classes for mortality (95%CI) 0.73 (0.68-0.75) 0.72 (0.66-0.77) 0.74 (0.62-0.86)
Initial proADM level (day 0)
ProADM, median (IQR) (nmol/l) 1.1 (0.7-1.7) 1.2 (0.8-1.9) 0.9 (0.6-1.3) <0.001
ProADM categories <0.001
ProADM <0.75 nmol/l, no (%) 353 (26.0%5) 194 (21.0%) 145 (38.3%)
ProADM: 0.75 - 1.5 nmol/l, no (%) 588 (43.3%) 400 (43.2%) 166 (43.8%)
ProADM >1.5 nmol/l, no (%) 418 (30.8%) 331 (35.8%) 68 (17.9%)
AUC of proADM for adverse events (95%CI) 0.73 (0.69-0.78) 0.71 (0.67-0.78) 0.76 (0.66-0.85)
AUC of proADM for mortality (95%CI) 0.79 (0.73-0.85) 0.76 (0.68-0.83) 0.88 (0.80-0.94)
AUC Area under the ROC curve; PSI Pneumonia Severity Index; CURB65 confusion, uremia, respiratory rate, blood pressure, age 65 years or greater; p value
relates to difference between CAP and non-CAP-LRTI; of note, some patients had more than one adverse event, thus the numbers may not sum up to 100%. *
Comparison CAP vs. Non-CAP
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low recommendations of a scoring system. For prognos-
tic purposes, ProADM is superior to PCT and other
biomarkers as shown by our group and others
[10,11,13,15]. These findings were largely confirmed in a
multicenter US study enrolling 1653 patients with CAP,
even though in the US study ProADM only added prog-
nostic value in patients with severe CAP (PSI classes
IV&V, CURB65 groups 2&3), while mortality in less
severe CAP (PSI classes I-III, CURB65 group 1) was low
irrespectively of ProADM values [14]. Our data confirm
that ProADM significantly improves the CURB65 score
for prediction of adverse events and in mortality in the
high CURB65 classes. Similarly, in our study patients
with low CURB65 classes (0-1) had low mortality with
ProADM tertiles providing no additional information
quoad vitam. However, increasing ProADM tertiles
were associated with significantly increased risk of
adverse events even in the low risk CURB65 classes.
Taken together, combining ProADM values with
CURB65 scores allows a more objective triage of
patients with LRTI presenting to the emergency depart-
ment. It improved the prediction of adverse events in
low CURB65 classes which might increase physicians’
compliance with triage decisions and their acceptance
by patients. Adherence to the combined risk score
CURB65-A would also improve the safety of patients
who formerly would have been discharged based on a
low CURB65 score but in fact carried an unacceptably
high risk of complications. Overall, the CURB65-A has
great potential to increase the number of secure outpati-
ent treatments by improved triage confidence and
compliance.
Another strength of this study is its design as a pre-
planned substudy of the randomized controlled multi-
center ProHOSP intervention trial. Since it involved
patients in large and medium-sized academic and non-
academic hospitals, the results will be largely generaliz-
able to many settings. This study provides evidence that
CURB65 performed similarly for outcome prediction in
CAP and non-CAP-LRTI patients, as recently reported
[6], importantly extending their clinical utility.
There are limitations of our study. In line with the
original ProHOSP study [20], we used a composite of
adverse events defined as all-cause mortality, ICU
admission, or any disease specific complications (i.e.
empyema in all cases) as our primary endpoint. While
this was done to incorporate clinically meaningful out-
comes in light of sample size considerations, there are
disadvantages of composite endpoints [44], such as dif-
ferences in the importance of each part of the compo-
site. One may argue that while all-cause mortality is an
objective endpoint, ICU admission depends in part on
the experience of the physician in charge, critical-care
bed availability and other “soft” factors; however, we dis-
played severity criteria within ProHOSP in order to
Figure 1 Estimated association between initial ProADM values and the risk of adverse events (A) and death (B). Estimated association
between initial ProADM values and the risk of adverse events (upper black line) and death (lower blue line). Estimates are based on generalized
additive models and shaded gray regions correspond to (point-wise) 95% confidence intervals. The rugs at the bottom of the plots display the
distribution of the biomarker. Solid lines (and confidence intervals) based on imputed data, dashed lines based on complete-case analysis.
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Page 6 of 12standardize ICU admission. In addition, all adverse
events were monitored by an independent data safety
and monitoring board. Still, because a high CURB65
score was one of the severity criteria which prompted
physicians to consider admitting patients to the ICU, its
prognostic performance may be artificially improved. As
a consequence, this would imply a rather conservative
bias in regard of the prognostic performance of
ProADM. In analogy to existing risk scores and
guideline recommendations, we only included medical
risk factors. However, for real-life triage decisions,
social, societal, organizational, functional factors and
preferences of patients and relatives also have to be
taken into account. In some settings these non-medical
factors might be even more important and lead to
reduced effectiveness of the algorithm. We are currently
planning an intervention study with a multidisciplinary
risk assessment including these factors to assess the
Figure 2 Observed and expected adverse events (A) and mortality (B) within CURB65 class 0/1 (low risk patients).O b s e r v e da n d
expected adverse events and mortality within CURB65 class 0/1 (low risk patients). A. Calibration of initial ProADM deciles and adverse events. B.
Calibration of ProADM deciles and mortality.
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Page 7 of 12efficacy of the CURB65-A score and the real-life effec-
tiveness of the interdisciplinary triage algorithm. Finally,
since the number of patients was higher in the CAP
than in the non-CAP-LRTI group and since our primary
endpoint was mainly driven by the outcomes in the
CAP group with relatively low mortality and adverse
event rates in the non-CAP-LRTI group, the utility of
the CURB65-A score for patients with non-CAP-LRTIs
is less certain. The similar results of the algorithm in
patients with and without CAP, however, are reassuring.
Nonetheless, this heterogeneous but clinically important
group of non-CAP-LRTI patients deserves particular
attention in future studies testing the CURB65-A score.
Conclusions
In conclusion, the combination of ProADM and
CURB65 in a novel risk score (CURB65-A) showed
improved performance for triaging patients with regard
Figure 3 Observed and expected adverse events (A) and mortality (B) within CURB65 class 3-5 (high risk patients).O b s e r v e da n d
expected adverse events and mortality within CURB65 class 3-5 (high risk patients). A. Calibration of ProADM deciles and adverse events. B.
Calibration of initial ProADM deciles and mortality.
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Page 8 of 12Table 3 Observed mortality rate according to risk class CURB65-A (based on ProADM and CURB65)
All LRTI patients (1359) CAP patients (n = 925)
n Adverse events (95%CI) Mortality
(95%CI)
n Adverse events (95%CI) Mortality
(95%CI)
CURB65 risk classes
CURB65 0-1 659 6.83 (4.9-8.76) 0.76 (0.09-1.42) 427 8.67 (5.99-11.34) 0.94 (0.02-1.85)
CURB65 2 434 14.75 (11.4-18.1) 8.06 (5.49-10.64) 296 15.54 (11.39-19.69) 8.45 (5.26-11.63)
CURB65 3-5 266 22.93 (17.85-28.02) 10.15 (6.5-13.8) 202 25.25 (19.21-31.29) 10.4 (6.15-14.64)
ProADM categories
ProADM <0.75 nmol/l 353 4.25 (2.13-6.36) 0.85 (-0.11-1.81) 194 5.67 (2.39-8.95) 1.55 (-0.21-3.3)
ProADM 0.75 - 1.5 nmol/l 588 9.01 (6.69-11.34) 2.72 (1.4-4.04) 400 10 (7.05-12.95) 2.75 (1.14-4.36)
ProADM >1.5 nmol/l 418 24.4 (20.27-28.54) 11.48 (8.41-14.55) 331 25.08 (20.38-29.77) 10.88 (7.5-14.25)
CURB65-A
Risk class 1 306 3.92 (1.73-6.11) 0.65 (0.25-1.56) 167 5.39 (1.93-8.85) 1.2 (0.47-2.86)
Risk class 2 534 8.61 (6.23-11) 2.62 (1.26-3.98) 360 9.72 (6.65-12.8) 2.78 (1.07-4.48)
Risk class 3 519 21.58 (18.03-25.13) 9.83 (7.26-12.4) 398 22.61 (18.49-26.74) 9.55 (6.65-12.45)
Total 1359 12.51 (10.75-14.27) 4.93 (3.78-6.08) 925 14.49 (12.21-16.76) 5.41 (3.95-6.87)
Figure 4 Combination of CURB65 risk classes and ProADM tertiles in all LRTI patients. Combination of CURB65 risk classes and initial
ProADM tertiles in all LRTI patients. A. Adverse events in CURB65 and ProADM categories. B. Mortality in CURB65 and ProADM categories. Risk
class I = green, risk class II = orange, risk class III = red.
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Page 9 of 12Figure 5 Combination of CURB65 risk classes and ProADM tertiles in CAP patients. Combination of CURB65 risk classes and initial ProADM
tertiles in CAP patients. A. Adverse events in CURB65 and ProADM categories. B. Mortality in CURB65 and ProADM categories. Risk class I =
green, risk class II = orange, risk class III = red.
Figure 6 Risk classification stratified for outpatients (A) and inpatients (B). Risk classification stratified for outpatients (A) and inpatients (B)
according to CURB65-A. Risk class I = green, risk class II = orange, risk class III = red.
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Page 10 of 12to expected risks for mortality and adverse outcomes
compared to CURB65 alone. Whether the theoretical
benefits will actually translate into real-life improve-
ments with improved safety by hospitalizing patients at
high risk and a greater effectiveness by recommending
ambulatory treatment for patients with LRTI at low risk
has to be answered by future intervention studies.
Abbreviation list
AUC: Area under the curve; CAP: community-acquired pneumonia; COPD:
chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic
Obstructive Lung Disease; ICU: intensive care unit; LRTI: lower respiratory
tract infection; ProADM: proadrenomedullin; PSI: pneumonia severity index;
ROC: receiver operating characteristic curve
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